In lung cancer, RUNX2 had an antiapoptotic effect, and a shRNA-mediated loss-of-function experiment resulted in increased dead cancer cells determined by positive annexin/propidium iodide (PI) in flow cytometry. This evidence concerns the gene RUNX2 and lung carcinoma.